Medivation Inc.'s stock-jolting Phase III blow-up with Dimebon (latrepirdine) for Alzheimer's disease imperiled the firm's deal with Pfizer Inc., triggered shareholder class-action lawsuits and upped the ante for already hard-pressed developers of AD therapies across the board. Read More
